Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale
Tezepelumab in Canadian Adults With Severe Chronic Rhinosinusitis With Nasal Polyps: A Subgroup Analysis of the Phase 3 WAYPOINT Trial
By Desrosiers M, Corriveau MN, Gagnon R and 7 others.
Abstract
Importance: Tezepelumab, a monoclonal antibody targeted against thymic stromal lymphopoietin, was recently approved in Canada for the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP). Its effectiveness specifically in the Canadian setting has not been evaluated.
Objective
To analyze the efficacy and safety of tezepelumab in Canadian patients enrolled in the WAYPOINT trial and contextualize the findings with respect to the Canadian healthcare environment.
Design
Post hoc analysis of a multinational, parallel-group, randomized, placebo-controlled, Phase 3 trial.